Collecting data on prostate cancer patients treated with Lu-PSMA therapy
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
This study is trying to learn more about how well Lu-PSMA therapy works for men with advanced prostate cancer by collecting data and blood samples from patients receiving the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam, South Holland) |
| Trial ID | NCT06260410 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data and blood biomarkers from patients receiving Lu-PSMA therapy for metastatic prostate cancer at Erasmus MC. By collecting real-world efficacy and safety data, the study seeks to understand the treatment's impact and identify potential biomarkers that could predict which patients benefit the most. Participants will undergo blood draws for ctDNA and circulating tumor cell collection as part of the data collection process.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are about to start Lu-PSMA treatment as part of their clinical care.
Not a fit: Patients who are not starting Lu-PSMA therapy or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of Lu-PSMA therapy's effectiveness and safety, leading to improved patient selection and outcomes.
How similar studies have performed: While this study focuses on real-world data collection, similar approaches in other studies have shown promise in understanding treatment efficacy and safety.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants should be at least 18 years old. * Participants should be able to understand the written information and be able to provide informed consent. * Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care. Exclusion Criteria: None applicable
Where this trial is running
Rotterdam, South Holland
- Erasmus MC — Rotterdam, South Holland, Netherlands (Recruiting)
Study contacts
- Study coordinator: Stijn Koolen, PhD
- Email: s.koolen@erasmusmc.nl
- Phone: +31638740656
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.